Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
Olmos D. et al, (2011), Clin Cancer Res, 17, 3420 - 3430
Does metabolic response at repeat PET/CT examination predict pathological response to neoadjuvant chemotherapy in oesophageal cancer?
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 7 - 7
METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22, 31 - 31
METFORMIN'S EFFECTS ON BREAST CANCER LIPID METABOLISM
Lord SR. et al, (2011), ANNALS OF ONCOLOGY, 22
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N. et al, (2011), Cancer Res, 71, 3317 - 3327
The biological and therapeutic relevance of mRNA translation in cancer.
Blagden SP. and Willis AE., (2011), Nat Rev Clin Oncol, 8, 280 - 291
Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
Gillies RS. et al, (2011), BRITISH JOURNAL OF SURGERY, 98, 3 - 3
Shared care protocol for the management of essential thrombocythaemia patients in primary care
Sweeney C. et al, (2011), BRITISH JOURNAL OF HAEMATOLOGY, 153, 55 - 55
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Khan OA. et al, (2011), Br J Cancer, 104, 750 - 755
Circulating melanoma cells and survival in metastatic melanoma.
Rao C. et al, (2011), Int J Oncol, 38, 755 - 760
Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
Gillies RS. et al, (2011), Eur Radiol, 21, 274 - 280
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.
Goardon N. et al, (2011), Cancer Cell, 19, 138 - 152
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
Khan OA. et al, (2011), British Journal of Cancer
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Leijen S. et al, (2011), Cancer Chemotherapy and Pharmacology, 1 - 10
CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
Ait-Tahar K. et al, (2011), Haematologica, 96, 78 - 86
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
Khan OA. et al, (2011), Br J Cancer, 104, 1822 - 1827
Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.
Cooper CDO. et al, (2011), PLoS One, 6
Molecular targets in ovarian cancer
Agarwal R. and Blagden S., (2011), Cancer and Chemotherapy Reviews, 6, 37 - 44
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer
Gungor H. et al, (2011), EUROPEAN JOURNAL OF CANCER, 47, 12 - 13